Similarly, empagliflozin has been shown to inhibit the function of Ca2+/calmodulin-dependent kinase II, leading to improved myocardial contractility and a reduction of arrhythmias among HF patients (Mustroph et al., 2018). Here, CA2 is linked to hydrops fetalis.